REGN
REGENERON PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$790.75
−0.70%Price chart
Sep 17Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16
Key dataOct 16, 2026
Open$803.01
From 52W high−7.19%
Volume245276.00
Market cap$81.41B
P/E (TTM)18.9x
P/S (TTM)5.2x
Div yield0.47%
Key dataOct 16, 2026
Open
$803.01
From 52W high
−7.19%
Volume
245276.00
Market cap
$81.41B
ValuationView details →
P/E (Fwd)
12.2x
EV/EBITDA
13.1x
P/E (TTM)
18.9x
RSI (14)
58.7
MomentumView details →
1D Return
−0.70%
YTD Return
+2.98%
SummaryUpdated Jun 1, 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a leading biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company went public in 1991 and has evolved from a research-focused startup into one of the world's premier biotechnology companies. Regeneron discovers, develops, manufactures, and commercializes innovative medicines for serious diseases across multiple therapeutic areas including ophthalmology, immunology, oncology, and rare diseases. The company is known for its proprietary drug discovery platforms and has built a portfolio of blockbuster medicines that serve patients worldwide.
Similar companies
Latest newsMore news →
Regeneron Pharmaceuticals agreed to dismiss its lawsuit against Sanofi over access to material information on Dupixent commercialization and audit rights under the Antibody License and Collaboration Agreement.10d agoRegeneron presented late-breaking Phase 3 C-POST data on adjuvant Libtayo (cemiplimab) for high-risk cutaneous squamous cell carcinoma after surgery and radiation at ESMO 2026.10d agoSanofi and Regeneron expanded their longstanding antibody collaboration, adding multiple next-generation long-acting immunology antibodies including REGN20423, with Regeneron receiving $1 billion upfront and up to $7 billion in future milestones.16d ago